Pretty not too long ago, preliminary results from a third trial evaluating ibrutinib compared to observation were being presented.a hundred and five Sufferers receiving ibrutinib experienced a longer function-absolutely free survival, but no All round survival gain, although the final results were being continue to immature. Moreover, Though signif